The effect of medication use on chronic pruritus in patients with type 2 diabetes mellitus: a multicenter cross-sectional study
Related Experiment Video
Updated: Mar 3, 2026

Cheek Injection Model for Simultaneous Measurement of Pain and Itch-related Behaviors
Published on: September 27, 2019
Min Xu1, Ximan Gao1, Zirong Liu2
1NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, 300134, People's Republic of China.
Abstract:
This study aimed to investigate the association between various types of medications and chronic pruritus (CP) in patients with type 2 diabetes mellitus (T2DM) through a large cross-sectional study. This study encompassed data from the Tianjin Community-Based Diabetic Retinopathy Screening Cohort, comprising 2,059 patients with T2DM who were enrolled from eight community centers. The exposure variables were different medication classes, and the outcome variable was CP symptoms. The prevalence of CP in patients with T2DM was 41.3% (851/2059). After adjusting for potential confounding factors, α-glucosidase inhibitor (AGIs) (adjusted OR 1.272, 95%CI 1.050–1.541), DPP-4 inhibitors (DPP-4is) (adjusted OR 1.286, 95%CI 1.006–1.642), and statins(adjusted OR 1.411, 95%CI 1.151–1.729) remained independently associated with higher odds of CP. In addition, the odds of CP increased progressively with the number of medications used (from one to three drugs; ORs ranging from 1.230 to 1.961). Subgroup analyses further identified a significant interaction between AGI use and renal impairment, with higher odds of CP observed among patients with renal impairment. (P for interaction < 0.05). CP in patients with T2DM was associated with the use of AGIs, DPP-4is, and statins. Moreover, a significant interaction was observed between renal impairment and the use of AGIs.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Type 2 and Gestational

